

<b>Reference:</b>	FOI.17859.25
<b>Subject:</b>	Haemophilia A & Prothrombin Complex Concentrate (PCC)
<b>Date of Request:</b>	20 July 2025

**Requested:**

**Haemophilia A**

1. In the past 12 months [latest 12 months available], how many patients have been diagnosed with the each of the following conditions in your Trust:
  - Haemophilia A
  - Acquired Haemophilia A (AHA)
  - Congenital Haemophilia A with inhibitors (CHAwI)
  
2. In the last twelve months[latest 12 months available], how many pts with Haemophilia A, have been treated with each of the following products in your Trust:
  - Factor Eight Inhibitor Bypass Activity (FEIBA)
  - Hemlibra (standalone)
  - Hemlibra in combination with NovoSeven RT
  - Hemlibra in combination with Cevenfacta
  - NovoSeven RT
  - Obizur
  - Cevenfacta
  
3. In the last twelve months[latest 12 months available], how many patients with Acquired Haemophilia A, have been treated with each of the following products in your Trust:
  - Factor Eight Inhibitor Bypass Activity (FEIBA)
  - NovoSeven RT
  - Obizur
  - Cevenfacta
  
4. In the last twelve months[latest 12 months available], how many pts with Congenital Haemophilia A with Inhibitors have been treated with each of the following products in your Trust?
  - Factor Eight Inhibitor Bypass Activity (FEIBA)
  - Hemlibra (standalone)
  - Hemlibra in combination with NovoSeven RT
  - Hemlibra in combination with Cevenfacta
  - Hemlibra in combination with FEIBA
  - Helimbra in combination with Factor VIII
  - NovoSeven RT
  - Obizur
  - Cevenfacta

**Prothrombin Complex Concentrate (PCC)**

5. What is the total Prothrombin Complex Concentrate usage in International Units (IUs) for your Trust over the last 12 months [latest 12 months available] for each of the products below in your Trust?

- Prothromplex
- Beriplex
- Octaplex

6. Can you share the Prothrombin Complex Concentrate usage in International Units for your Trust in the last 12 months [latest 12 months available] within each of the following departments, and which PCC is used?

- Prothromplex
- Beriplex
- Octaplex

Departments

Cardio-speciality  
General Medicine  
General surgery  
Haematology  
Emergency care  
Any other

**Response:**

Hywel Dda University Health Board (UHB) regrets to inform you that it does not hold the information requested for questions 1, 2, 3 and 4. The UHB's patients that require Haemophilia treatment are seen and treated by Cardiff and Vale University Health Board (C&V UHB).

Therefore, we recommend that you redirect this part of your request to the Freedom of Information Team at C&V UHB, who may be able to help you further. Their contact details are as follows:

[FOI.Requests@wales.nhs.uk](mailto:FOI.Requests@wales.nhs.uk)

However, whilst operating in accordance with the Section 45 Freedom of Information Code of Practice, the UHB has a duty to provide advice and assistance and can confirm that although patients who require Haemophilia treatment are treated by C&V UHB, they arrange for the products to be shipped by our blood banks. Therefore, the UHB provides the information it holds below.

1. Not held.
2. The UHB confirms zero (0) patients with Haemophilia A have been treated with any of the listed products, during the period 1 July 2024 to 30 June 2025.
3. The UHB confirms zero (0) patients with Acquired Haemophilia A have been treated with any of the listed products, during the period 1 July 2024 to 30 June 2025.
4. The UHB confirms zero (0) patients with Congenital Haemophilia A with Inhibitors have been treated with any of the listed products, during the period 1 August 2024 to 1 August 2025.
5. The UHB provides within the table overleaf, the total usage of Prothrombin Complex Concentrate in International Units (IUs), during the period 1 August 2024 to 1 August 2025.

<b>Product</b>	<b>IU</b>
Prothromplex	0
Beriplex	0
Octaplex	425,400
<b>Total</b>	<b>425,400</b>

6. The UHB provides within the table below, the total usage of Prothrombin Complex Concentrate in IUs, split by concentrate and department, during the period 1 August 2024 to 1 August 2025.

<b>Department</b>	<b>Octaplex</b>
Cardio-speciality	4,500
General Medicine	47,500
General Surgery	62,000
Haematology	1,500
Emergency Care	207,400
Any other	102,500
<b>Total</b>	<b>425,400</b>